<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-535" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hot Flashes</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lugo</surname>
            <given-names>Tania</given-names>
          </name>
          <aff>Nassau University Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tetrokalashvili</surname>
            <given-names>Maggie</given-names>
          </name>
          <aff>Nassau Ubiversity Medical center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tania Lugo declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Maggie Tetrokalashvili declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>19</day>
          <month>12</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-535.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Hot flashes are sudden-onset, spontaneous, and episodic sensations of warmth usually felt on the chest, neck, and face immediately followed by sweating. They are the most common reason women seek medical care during the perimenopausal period, especially if the symptoms impair their quality of life. The onset of hot flashes can be associated with perspiration, heart palpitations, headache, weakness, fatigue, faintness, and anxiety, and warm environments, hot drinks, or emotional stress can trigger them. This activity reviews the presentation, evaluation, and management of hot flashes and stresses the role of an interprofessional team approach to the care of affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of hot flashes.</p></list-item><list-item><p>Determine&#x000a0;the history and physical exam findings typically seen in patients with hot flashes.</p></list-item><list-item><p>Identify&#x000a0;the management options for hot flashes.</p></list-item><list-item><p>Communicate&#x000a0;the modalities to improve care coordination among interprofessional team members in order to improve outcomes for patients affected by hot flashes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=535&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=535">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-535.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Hot flashes are sudden-onset, spontaneous, and episodic sensations of warmth usually felt on the chest, neck, and face immediately followed by sweating.&#x000a0;They are the most common reason women seek medical care during the perimenopausal period, especially if the symptoms impair quality of life.<xref ref-type="bibr" rid="article-535.r1">[1]</xref> The onset of hot flashes can be associated with perspiration, heart palpitations, headache, weakness, fatigue, faintness, and anxiety, and warm environments, hot drinks, or emotional stress can trigger them. Hot flashes are variable in terms of duration, severity, and frequency. Frequency and severity can increase during the transition to menopause and peak approximately&#x000a0;1 year after the final menstrual period.<xref ref-type="bibr" rid="article-535.r2">[2]</xref>&#x000a0;They can persist for&#x000a0;6 months to several years, usually decreasing in frequency and intensity over time after the final menstrual period.<xref ref-type="bibr" rid="article-535.r2">[2]</xref>&#x000a0;On average, they last less than&#x000a0;5 minutes. The average frequency varies from 10 times daily to several times weekly.<xref ref-type="bibr" rid="article-535.r2">[2]</xref>&#x000a0;The mean duration is 1.2 years.<xref ref-type="bibr" rid="article-535.r2">[2]</xref></p>
      </sec>
      <sec id="article-535.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The exact pathogenesis of hot flashes is unknown, but studies indicate that VMS (vasomotor symptoms)&#x000a0;results from a central thermoregulatory function defect.<xref ref-type="bibr" rid="article-535.r1">[1]</xref> The physiological changes accompanying VMS are clear and well documented, yet several hypotheses about the mechanism of action exist. Various hormones and neurotransmitters modulate vasomotor symptoms, most importantly, estrogen. The thinking is that ovarian estrogen withdrawal is the initial mechanism leading to hot flashes. Norepinephrine and serotonin also have a role in the defect in thermoregulation with VMS, which is why SSRIs and SNRIs have been used to treat VMS.<xref ref-type="bibr" rid="article-535.r1">[1]</xref> Research documents that plasma levels of norepinephrine metabolites rise before and during a hot flash.<xref ref-type="bibr" rid="article-535.r1">[1]</xref> Peripheral vasodilation occurs, increasing to 10 to 15 degrees C in the fingers and toes.<xref ref-type="bibr" rid="article-535.r3">[3]</xref> A rise in systolic blood pressure and heart rate also occurs.<xref ref-type="bibr" rid="article-535.r4">[4]</xref></p>
      </sec>
      <sec id="article-535.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Hot flashes are among the most common types of menopausal vasomotor symptoms (VMS), affecting up to 74% of perimenopausal women.<xref ref-type="bibr" rid="article-535.r1">[1]</xref>&#x000a0;Sixty-five&#x000a0;percent of women complain of hot flashes for more than&#x000a0;2 years, and 36% for more than&#x000a0;5 years.<xref ref-type="bibr" rid="article-535.r2">[2]</xref></p>
      </sec>
      <sec id="article-535.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Screening for hot flashes should take place in all perimenopausal women. Hot flashes should also receive treatment if they impair a woman's quality of life, particularly daytime activities and sleep. At the same time, many women have hot flashes and do not need treatment. In the most severe cases, a woman can awake several times during the night, which, in the&#x000a0;long term, can cause cognitive and anxiety disorders.</p>
      </sec>
      <sec id="article-535.s6" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Several treatment options exist, with only a few being FDA-approved. When selecting a treatment option, the healthcare provider should encourage the safest option first, such as lifestyle changes, and then proceed to the following hormonal or non-hormonal treatments. The most effective treatment for hot flashes is systemic estrogen, with a 75% reduction in VMS frequency.<xref ref-type="bibr" rid="article-535.r5">[5]</xref> Progestin therapy at high doses, including DMPA and megestrol, also decreases hot flashes but is not nearly as effective as estrogen.<xref ref-type="bibr" rid="article-535.r6">[6]</xref>&#x000a0; Progesterone treatment should be a consideration in women who cannot take estrogen therapy. Hormone therapy (HT) administration can be in various forms, including oral, parenteral, topical, transbuccal, vaginal, or transdermal, with each route having various formulations and doses of estrogen or progesterone.<xref ref-type="bibr" rid="article-535.r7">[7]</xref> The consensus is that HT for the treatment of hot flashes or vasomotor symptoms should be prescribed at the lowest effective dose for the shortest amount of time needed to manage the symptoms.<xref ref-type="bibr" rid="article-535.r6">[6]</xref> The safety of HT is controversial.</p>
        <p>The Women's Health Initiative (WHI) is the largest study&#x000a0;of its kind that evaluated hormone therapy risks in menopausal women. It was a multicenter, double-blind, placebo-controlled trial of women aged 50 to 79 at baseline, designed to assess HT&#x02019;s impact on cardiovascular disease. Initial findings of the WHI reported that combined HT was not cardioprotective.<xref ref-type="bibr" rid="article-535.r8">[8]</xref> The WHI also found that HT increased the incidence of breast cancer, thromboembolic events, and stroke.<xref ref-type="bibr" rid="article-535.r9">[9]</xref>&#x000a0;It is contraindicated in women with a history of breast cancer.<xref ref-type="bibr" rid="article-535.r10">[10]</xref>&#x000a0; As a result of the WHI findings, the current recommendation for the use of HT is to treat moderate to severe vasomotor symptoms at the lowest possible dose. An alternative to the conventional HT is compounded bioidentical hormones. Still, there is no evidence that these compounded products are as safe, effective, or superior to conventional HT for treating vasomotor symptoms.<xref ref-type="bibr" rid="article-535.r11">[11]</xref> Bioidentical hormone products currently FDA-approved include 17B-estradiol (transdermal or oral) and micronized progesterone (oral or vaginal). Non-FDA-approved bioidentical HT includes compounded preparations.<xref ref-type="bibr" rid="article-535.r7">[7]</xref><xref ref-type="bibr" rid="article-535.r12">[12]</xref></p>
        <p>Since 2002, after the initial findings of the WHI were published, the use of HT decreased substantially (as much as 80%) as patients and providers turned to alternate forms of managing VMS.<xref ref-type="bibr" rid="article-535.r13">[13]</xref><xref ref-type="bibr" rid="article-535.r14">[14]</xref>&#x000a0; Non-prescribed, nonhormonal&#x000a0;therapies studied include soy extract, red clover isoflavones, black cohosh, and Chinese herbs. Their safety and efficacy remain unclear. Although better quality studies are needed, some studies have found these nonhormonal options less effective than placebos.<xref ref-type="bibr" rid="article-535.r9">[9]</xref><xref ref-type="bibr" rid="article-535.r12">[12]</xref>&#x000a0;</p>
        <p>Prescription nonhormonal therapies include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Gabapentin/pregabalin</p>
          </list-item>
          <list-item>
            <p>Clonidine</p>
          </list-item>
          <list-item>
            <p>SSRIs (paroxetine)</p>
          </list-item>
          <list-item>
            <p>SNRIs (venlafaxine, desvenlafaxine)</p>
          </list-item>
        </list>
        <p>These medications are more effective than placebos but not as effective as hormonal therapy.<xref ref-type="bibr" rid="article-535.r9">[9]</xref>&#x000a0; Paroxetine was the first nonhormonal prescription medication that was FDA-approved for use in treating menopausal vasomotor symptoms, including hot flashes.<xref ref-type="bibr" rid="article-535.r15">[15]</xref> The typically prescribed dose is an ultra-low 7.5 mg daily. It moderately reduces hot flashes versus the placebo.<xref ref-type="bibr" rid="article-535.r15">[15]</xref>&#x000a0;Paroxetine and other SSRIs are not recommended for women with tamoxifen-induced hot flashes due to their effects as a strong inhibitor of the drug-metabolizing enzyme CYP2D6, therefore interfering with tamoxifen's therapeutic benefit.<xref ref-type="bibr" rid="article-535.r16">[16]</xref>&#x000a0;SNRIs such as venlafaxine, although not FDA-approved for the treatment of hot flashes, are recommended for the management of hot flashes in a woman taking tamoxifen.<xref ref-type="bibr" rid="article-535.r16">[16]</xref> Other options for women with a history of breast cancer include gabapentin and clonidine.<xref ref-type="bibr" rid="article-535.r16">[16]</xref></p>
        <p>Lifestyle changes such as exercise, layering clothes, maintaining lower room temperature, drinking cool drinks, and avoiding caffeine and alcohol are reasonable to consider for managing VMS, even if there aren't conclusive studies proving their efficacy.<xref ref-type="bibr" rid="article-535.r17">[17]</xref> Unfortunately, only limited studies exist for nonmedicated and integrative medical treatments of hot flashes, but research is growing in the integrative medicine field. Integrative medical treatments, including breathing exercises, relaxation techniques, changes in diet, yoga, acupuncture, reflexology, and hypnosis, could relieve vasomotor symptoms.<xref ref-type="bibr" rid="article-535.r18">[18]</xref></p>
      </sec>
      <sec id="article-535.s7" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Hot flashes are most commonly associated with perimenopause and menopause. In any woman presenting with hot flashes, whether she is perimenopausal age or status-post surgical or medically induced menopause, pathology must be ruled out as the cause. Menopause can be confirmed by the cessation of menses for at least 12 months and estradiol and FSH levels.</p>
        <p>The differential diagnosis for hot flashes includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Carcinoid tumors</p>
          </list-item>
          <list-item>
            <p>Systemic mastocytosis</p>
          </list-item>
          <list-item>
            <p>Medullary carcinoma of the thyroid</p>
          </list-item>
          <list-item>
            <p>Pheochromocytoma</p>
          </list-item>
          <list-item>
            <p>Hyperthyroidism</p>
          </list-item>
          <list-item>
            <p>Acromegaly</p>
          </list-item>
          <list-item>
            <p>Idiopathic anaphylaxis&#x000a0;<xref ref-type="bibr" rid="article-535.r19">[19]</xref></p>
          </list-item>
        </list>
        <p>Medications&#x000a0;that can&#x000a0;also cause hot flashes include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Depo leuprolide</p>
          </list-item>
          <list-item>
            <p>Clomiphene</p>
          </list-item>
          <list-item>
            <p>Tamoxifen</p>
          </list-item>
          <list-item>
            <p>Raloxifene</p>
          </list-item>
          <list-item>
            <p>Tricyclic antidepressants</p>
          </list-item>
          <list-item>
            <p>Monoamine oxidase inhibitors</p>
          </list-item>
          <list-item>
            <p>Calcium channel blockers</p>
          </list-item>
          <list-item>
            <p>Serotonin uptake inhibitors</p>
          </list-item>
          <list-item>
            <p>Chemotherapy&#x000a0;<xref ref-type="bibr" rid="article-535.r19">[19]</xref></p>
          </list-item>
        </list>
        <p>Hot flashes are a common (up to 80%) side effect in women taking tamoxifen.<xref ref-type="bibr" rid="article-535.r1">[1]</xref></p>
      </sec>
      <sec id="article-535.s8" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of hot flashes is good. Most women's hot flashes resolve after 5 years. Only 10% of women have symptoms in the past 10 years.<xref ref-type="bibr" rid="article-535.r2">[2]</xref></p>
      </sec>
      <sec id="article-535.s9" sec-type="Complications">
        <title>Complications</title>
        <p>Nighttime hot flashes&#x000a0;can awaken the patient&#x000a0;and, over time, cause long-term sleep disruption. Research suggests&#x000a0;that women with hot flashes may&#x000a0;demonstrate an increased risk of&#x000a0;cardiac disease and&#x000a0;osteoporosis than women who do not have them.</p>
      </sec>
      <sec id="article-535.s10" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>A patient's first source of information should be their primary care provider or obstetrician and gynecologist. Patients can access patient education material online at the American College of Obstetricians, the American Society of Reproductive Specialists, and the North American Menopause Society.</p>
      </sec>
      <sec id="article-535.s11" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Key facts to keep in mind about&#x000a0;hot flashes are as follows:</p>
        <list list-type="order">
          <list-item>
            <p>Hot flashes are the most prevalent vasomotor symptom that presents during perimenopause.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The only FDA-approved nonhormonal prescription medication to treat hot flashes is low-dose paroxetine of 7.5 mg daily.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Nonhormonal nonprescription therapies, including black cohosh, red clover isoflavones, soy extract, and Chinese herbs, are not effective.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The Women's Health Initiative (WHI) found that combined HT raises the risk of breast cancer, venous thromboembolism, and stroke, is not cardioprotective, and does not decrease mortality risk.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The evidence is lacking to support the safety, effectiveness, and superiority of compounded bioidentical hormones over conventional hormone therapy.</p>
          </list-item>
          <list-item>
            <p>Although some SSRIs and SNRIs are safe and effective in treating hot flashes in patients with breast cancer, caution is necessary when used with tamoxifen. Gabapentin and clonidine can be alternatives for these patients.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-535.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Shared decision-making and communication between the gynecologist, nurse practitioner, primary care provider, nursing staff, pharmacy, and patient are critical in managing hot flashes. The patient should be well educated on her diagnosis, what to expect during the perimenopausal period, and her treatment options, including the risks, benefits, and alternatives of each therapy. They should receive counsel that HT has been proven safe and effective in treating VMS. They should receive education about the FDA approval status of the different forms of therapies. All these approaches are best handled by an interprofessional team incorporating the abovementioned personnel to deliver optimal patient care during menopause. Ambulatory care nurses are often the first contact for patients. After diagnosis,&#x000a0;clinicians&#x000a0;should monitor patients and provide follow-up to the interprofessional team. Pharmacists educate patients about side effects and compliance and check for drug interactions.</p>
      </sec>
      <sec id="article-535.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=535&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=535">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/hot-flashes/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=535">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/535/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=535">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-535.s14">
        <title>References</title>
        <ref id="article-535.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rapkin</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Vasomotor symptoms in menopause: physiologic condition and central nervous system approaches to treatment.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>196</volume>
            <issue>2</issue>
            <fpage>97</fpage>
            <page-range>97-106</page-range>
            <pub-id pub-id-type="pmid">17306645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-535.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Politi</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Schleinitz</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Col</surname>
                <given-names>NF</given-names>
              </name>
            </person-group>
            <article-title>Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis.</article-title>
            <source>J Gen Intern Med</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>23</volume>
            <issue>9</issue>
            <fpage>1507</fpage>
            <page-range>1507-13</page-range>
            <pub-id pub-id-type="pmid">18521690</pub-id>
          </element-citation>
        </ref>
        <ref id="article-535.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freedman</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>Physiology of hot flashes.</article-title>
            <source>Am J Hum Biol</source>
            <year>2001</year>
            <season>Jul-Aug</season>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>453</fpage>
            <page-range>453-64</page-range>
            <pub-id pub-id-type="pmid">11400216</pub-id>
          </element-citation>
        </ref>
        <ref id="article-535.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gerber</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Sievert</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Warren</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pickering</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Hot flashes are associated with increased ambulatory systolic blood pressure.</article-title>
            <source>Menopause</source>
            <year>2007</year>
            <season>Mar-Apr</season>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>308</fpage>
            <page-range>308-15</page-range>
            <pub-id pub-id-type="pmid">17213753</pub-id>
          </element-citation>
        </ref>
        <ref id="article-535.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maclennan</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Broadbent</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Lester</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2004</year>
            <month>Oct</month>
            <day>18</day>
            <volume>2004</volume>
            <issue>4</issue>
            <fpage>CD002978</fpage>
            <pub-id pub-id-type="pmid">15495039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-535.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nelson</surname>
                <given-names>HD</given-names>
              </name>
            </person-group>
            <article-title>Menopause.</article-title>
            <source>Lancet</source>
            <year>2008</year>
            <month>Mar</month>
            <day>01</day>
            <volume>371</volume>
            <issue>9614</issue>
            <fpage>760</fpage>
            <page-range>760-70</page-range>
            <pub-id pub-id-type="pmid">18313505</pub-id>
          </element-citation>
        </ref>
        <ref id="article-535.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <collab>North American Menopause Society</collab>
            <article-title>The 2012 hormone therapy position statement of: The North American Menopause Society.</article-title>
            <source>Menopause</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>257</fpage>
            <page-range>257-71</page-range>
            <pub-id pub-id-type="pmid">22367731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-535.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hodis</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Mack</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Henderson</surname>
                <given-names>VW</given-names>
              </name>
              <name>
                <surname>Shoupe</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Budoff</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Hwang-Levine</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dustin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kono</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Stanczyk</surname>
                <given-names>FZ</given-names>
              </name>
              <name>
                <surname>Selzer</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Azen</surname>
                <given-names>SP</given-names>
              </name>
              <collab>ELITE Research Group</collab>
            </person-group>
            <article-title>Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol.</article-title>
            <source>N Engl J Med</source>
            <year>2016</year>
            <month>Mar</month>
            <day>31</day>
            <volume>374</volume>
            <issue>13</issue>
            <fpage>1221</fpage>
            <page-range>1221-31</page-range>
            <pub-id pub-id-type="pmid">27028912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-535.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rossouw</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Prentice</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>LaCroix</surname>
                <given-names>AZ</given-names>
              </name>
              <name>
                <surname>Kooperberg</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stefanick</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Beresford</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>BV</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Kotchen</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Ockene</surname>
                <given-names>J</given-names>
              </name>
              <collab>Writing Group for the Women's Health Initiative Investigators</collab>
            </person-group>
            <article-title>Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.</article-title>
            <source>JAMA</source>
            <year>2002</year>
            <month>Jul</month>
            <day>17</day>
            <volume>288</volume>
            <issue>3</issue>
            <fpage>321</fpage>
            <page-range>321-33</page-range>
            <pub-id pub-id-type="pmid">12117397</pub-id>
          </element-citation>
        </ref>
        <ref id="article-535.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holmberg</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>H</given-names>
              </name>
              <collab>HABITS steering and data monitoring committees</collab>
            </person-group>
            <article-title>HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped.</article-title>
            <source>Lancet</source>
            <year>2004</year>
            <month>Feb</month>
            <day>07</day>
            <volume>363</volume>
            <issue>9407</issue>
            <fpage>453</fpage>
            <page-range>453-5</page-range>
            <pub-id pub-id-type="pmid">14962527</pub-id>
          </element-citation>
        </ref>
        <ref id="article-535.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boothby</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Doering</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Kipersztok</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Bioidentical hormone therapy: a review.</article-title>
            <source>Menopause</source>
            <year>2004</year>
            <season>May-Jun</season>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>356</fpage>
            <page-range>356-67</page-range>
            <pub-id pub-id-type="pmid">15167316</pub-id>
          </element-citation>
        </ref>
        <ref id="article-535.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shifren</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Gass</surname>
                <given-names>ML</given-names>
              </name>
              <collab>NAMS Recommendations for Clinical Care of Midlife Women Working Group</collab>
            </person-group>
            <article-title>The North American Menopause Society recommendations for clinical care of midlife women.</article-title>
            <source>Menopause</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>21</volume>
            <issue>10</issue>
            <fpage>1038</fpage>
            <page-range>1038-62</page-range>
            <pub-id pub-id-type="pmid">25225714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-535.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jewett</surname>
                <given-names>PI</given-names>
              </name>
              <name>
                <surname>Gangnon</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Trentham-Dietz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sprague</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Trends of postmenopausal estrogen plus progestin prevalence in the United States between 1970 and 2010.</article-title>
            <source>Obstet Gynecol</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>124</volume>
            <issue>4</issue>
            <fpage>727</fpage>
            <page-range>727-733</page-range>
            <pub-id pub-id-type="pmid">25198271</pub-id>
          </element-citation>
        </ref>
        <ref id="article-535.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manson</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Kaunitz</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Menopause Management--Getting Clinical Care Back on Track.</article-title>
            <source>N Engl J Med</source>
            <year>2016</year>
            <month>Mar</month>
            <day>03</day>
            <volume>374</volume>
            <issue>9</issue>
            <fpage>803</fpage>
            <page-range>803-6</page-range>
            <pub-id pub-id-type="pmid">26962899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-535.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simon</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Portman</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Kaunitz</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Mekonnen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kazempour</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bhaskar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lippman</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials.</article-title>
            <source>Menopause</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>20</volume>
            <issue>10</issue>
            <fpage>1027</fpage>
            <page-range>1027-35</page-range>
            <pub-id pub-id-type="pmid">24045678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-535.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Desmarais</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Looper</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>Managing menopausal symptoms and depression in tamoxifen users: implications of drug and medicinal interactions.</article-title>
            <source>Maturitas</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>296</fpage>
            <page-range>296-308</page-range>
            <pub-id pub-id-type="pmid">20880642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-535.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thurston</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Joffe</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Vasomotor symptoms and menopause: findings from the Study of Women's Health across the Nation.</article-title>
            <source>Obstet Gynecol Clin North Am</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>38</volume>
            <issue>3</issue>
            <fpage>489</fpage>
            <page-range>489-501</page-range>
            <pub-id pub-id-type="pmid">21961716</pub-id>
          </element-citation>
        </ref>
        <ref id="article-535.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <article-title>ACOG Practice Bulletin No. 141: management of menopausal symptoms.</article-title>
            <source>Obstet Gynecol</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>123</volume>
            <issue>1</issue>
            <fpage>202</fpage>
            <page-range>202-216</page-range>
            <pub-id pub-id-type="pmid">24463691</pub-id>
          </element-citation>
        </ref>
        <ref id="article-535.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Izikson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>English</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Zirwas</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>The flushing patient: differential diagnosis, workup, and treatment.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2006</year>
            <month>Aug</month>
            <volume>55</volume>
            <issue>2</issue>
            <fpage>193</fpage>
            <page-range>193-208</page-range>
            <pub-id pub-id-type="pmid">16844500</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
